EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

Alex E Henney iD, Megan Heague, David R Riley, Theresa J Hydes, Matthew Anson iD, Uazman Alam, Daniel J Cuthbertson

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Alex E Henney und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metformin and glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs ) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes ( T2D ). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body weight.

Methods

A retrospective cohort analysis was conducted using a large global database ( TriNetX ) of patients with T2D . Three cohorts: single agent use with metformin or GLP ‐1 RAs , and dual/combination metformin/ GLP ‐1 RA use, were compared with a reference group treated with DPP4 inhibitors ( DPP4i ). Propensity score matching (1:1) was applied to control for confounders. Cancer incidence and all cause mortality were assessed over 5 years of follow up.

Results

After matching, metformin and GLP ‐1 RA treatment were both associated with a lower risk of all adiposity‐related cancers and all‐cause mortality; the latter was associated with greater reductions in both. Cancer rates were (hazard ratio) 0.96 [95% CI 0.92, 0.99] and 0.86 [0.82, 0.89], while mortality rates were 0.78 [0.76, 0.80] and 0.61 [0.59, 0.63] for metformin and GLP ‐1 RA , respectively. Dual therapy showed the strongest association with lower cancer incidence (0.61 [0.57, 0.65]) and mortality (0.33 [0.32, 0.35]). Results were more significant in younger, male patients with obesity.

Conclusion

In patients with T2D, dual metformin and GLP‐1 RA treatment was associated with a 39% lower incidence of adiposity‐related cancers and a 67% lower mortality, with a striking impact on cancer‐related outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsNeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsAdiposityHumansMaleFemaleMiddle AgedRetrospective StudiesIncidenceAgedDrug Therapy, CombinationDrug SynergismDipeptidyl-Peptidase IV InhibitorsObesity

Stichwörter der Autor:innen

GLP‐1 analoguecohort studymetforminreal‐world evidencetype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.
  • Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, UK.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, UK.
  • Visiting Fellow, Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University, Stoke-on-Trent, UK.

ORCID-Profile: Alex E Henney, Matthew Anson

Zitieren

APA

Henney, A. E., Heague, M., Riley, D. R., Hydes, T. J., Anson, M., Alam, U., & Cuthbertson, D. J. (2026). Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70267

Vancouver

Henney AE, Heague M, Riley DR, Hydes TJ, Anson M, Alam U, et al. Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70267

BibTeX
@article{Henney2026,
  author = {Henney, Alex E and Heague, Megan and Riley, David R and Hydes, Theresa J and Anson, Matthew and Alam, Uazman and Cuthbertson, Daniel J},
  title = {Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70267}
}
Kostenlos starten →